National Guideline Clearinghouse | Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia.

Guideline Title
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia.

Bibliographic Source(s)
National Institute for Health and Clinical Excellence (NICE). Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Jul. 36 p. (Technology appraisal guidance; no. 193).

Guideline Status
This is the current release of the guideline.

full-text:
National Guideline Clearinghouse | Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia.